Welcome to our dedicated page for Moleculin Biotec SEC filings (Ticker: MBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Moleculin Biotech, Inc. (Nasdaq: MBRX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central to understanding Moleculin’s progress as a Phase 3 clinical stage pharmaceutical company focused on hard-to-treat tumors and certain viral infections.
Through Moleculin’s Form 8-K current reports, investors can review material events such as clinical and scientific milestones, corporate presentations, patent developments, financing transactions and listing-related communications. Recent 8-K filings have furnished press releases on positive Phase 1 results for WP1066 in pediatric recurrent malignant brain tumors, updates on enrollment and unblinding plans for the pivotal MIRACLE Phase 2B/3 AML trial of Annamycin plus cytarabine (AnnAraC), and independent assessments of Annamycin’s cardiotoxicity profile. Other 8-Ks describe grant-funded and investigator-initiated research agreements for Annamycin in pancreatic cancer and glioblastoma multiforme, as well as patent grants for preliposomal Annamycin lyophilizates.
Moleculin’s filings also document capital markets and listing matters, including notices from Nasdaq regarding bid price and stockholders’ equity requirements, the company’s responses and appeal plans, and the implementation of a 1-for-25 reverse stock split with continued trading under the MBRX symbol. Additional filings cover warrant exercises, special stockholder meeting results and approvals related to equity issuances.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and are paired with AI-powered summaries that highlight key points, such as clinical trial status, regulatory designations, patent protections and financing terms. Users can quickly scan 8-Ks and related reports to understand how Moleculin is advancing Annamycin, WP1066 and WP1122, how it is managing its Nasdaq listing, and how corporate actions may affect shareholders. This page also helps surface insider and governance-related information when reported through the company’s SEC submissions.
Moleculin Biotech, Inc. filed a prospectus to register up to 6,367,956 shares of its common stock for resale by selling stockholders. The registered shares are issuable upon exercise of newly issued warrants (the “Warrants”) from a February 2026 warrant inducement offer.
Shares outstanding were 5,336,350 as of March 11, 2026. The Warrants have an exercise price of $2.3976 per share, will be exercisable following shareholder approval of the issuance of the Inducement Warrant Shares, and include a Beneficial Ownership Limitation (holders may elect either 4.99% or 9.99%). The company will only receive cash proceeds if holders elect cash exercise; full cash exercise of all underlying warrants at the initial exercise price would result in gross proceeds of $15.3 million.
Moleculin Biotech announced enrollment of the 45th subject in its pivotal Phase 2B/3 MIRACLE trial of Annamycin plus cytarabine (AnnAraC) for adults with relapsed or refractory acute myeloid leukemia. This completes the threshold for an interim data unblinding targeted for mid-2026.
The interim analysis is expected to include about 30 AnnAraC-treated patients and 15 control patients on cytarabine plus placebo, providing early insight into efficacy, safety, and dose selection as the study advances toward its Phase 3 portion and a potential accelerated approval pathway based on complete remission.
Moleculin Biotech, Inc. furnished a new corporate presentation as Exhibit 99.1. The company states this presentation is being used for its corporate presentation and is also posted on its website. The material is provided under Item 7.01 and is furnished, not filed, under the Exchange Act.
Moleculin Biotech reported a 2025 net loss of $33.6M, with research and development expenses of $15.9M and general and administrative plus depreciation and amortization expenses of $9.2M. Cash and cash equivalents were $8.9M as of December 31, 2025, and management expects existing cash plus $8.3M of first‑quarter 2026 financing proceeds to fund operations into the third quarter of 2026.
The company highlighted rapid progress in its pivotal global MIRACLE trial of Annamycin plus cytarabine (AnnAraC) for relapsed or refractory AML. Blinded preliminary data from the first 30 subjects showed a composite complete remission rate of 40%, including 30% complete remission and 10% CRh, across six countries, despite roughly 35% of subjects having prior venetoclax exposure and other high‑risk features. An initial 45‑patient interim unblinding is planned for mid‑2026 as part of the adaptive Phase 2B/3 design.
Moleculin Biotech, Inc. is a late-stage pharmaceutical development company focused on oncology, led by its anthracycline candidate Annamycin. The drug is in the global Phase 2B/3 MIRACLE trial for relapsed/refractory acute myeloid leukemia, with interim data unblindings planned for mid-2026 and the second half of 2026.
Across multiple AML and soft tissue sarcoma lung metastases studies, Annamycin has shown human activity and, in over 90 treated subjects, independent experts have reported no evidence of cardiotoxicity, even above traditional lifetime anthracycline dose limits. The program holds Orphan Drug and Fast Track designations in AML and soft tissue sarcoma.
The company also advances two additional technology portfolios: WP1066, a STAT3-focused immune/transcription modulator platform with externally funded brain tumor trials and encouraging early pediatric data, and WP1122, a glycolysis/glycosylation inhibitor platform with a completed Phase 1a study and a Recommended Phase 2 Dose established.
Moleculin Biotech, Inc. has called a special stockholder meeting on April 15, 2026 to vote on three key items. The main proposal seeks approval, under Nasdaq Listing Rule 5635(d), to allow the exercise of warrants for up to 6,367,956 new common shares at an initial exercise price of $2.3976 per share, which could raise about $15.3 million if fully exercised for cash and would significantly dilute current holders relative to the 4,933,110 shares outstanding as of February 20, 2026. Stockholders will also vote on changing the company’s name to Moleculin Inc. and on authorizing adjournment of the meeting, if needed, to gather additional proxies in favor of the two main proposals.
Moleculin Biotech, Inc. is asking shareholders to approve three proposals at a Special Meeting on April 15, 2026. The primary item seeks shareholder approval to permit up to 6,367,956 shares of common stock to be issued upon exercise of Series H warrants issued February 20, 2026; those Warrants will only become exercisable upon shareholder approval.
The proxy also asks shareholders to approve a corporate name change to Moleculin Inc. and to authorize adjournment of the meeting if additional solicitation of proxies is needed. Shares outstanding were 4,933,110 as of February 20, 2026, and the company states that full cash exercise of the Warrants at the initial exercise price would yield $15.3 million.
Moleculin Biotech entered into warrant exercise inducement agreements with holders of existing warrants to buy up to 2,122,652 shares at $3.90 per share. The company expects aggregate gross proceeds of up to approximately $8.3 million from these exercises before fees.
In return, Moleculin will issue new Series H Inducement Warrants to purchase up to 6,367,956 shares, equal to 300% of the exercised shares. These warrants will have a five-year term and an exercise price per share equal to the lesser of $3.90 and the lowest volume-weighted average price over the five trading days after the public announcement, subject to shareholder approval. The warrants include price-adjustment features with a floor of $0.962, beneficial ownership limits of 4.99% or 9.99%, and cashless exercise under certain conditions.
Moleculin Biotech, Inc. filed a current report to make investors aware that it is using an updated corporate presentation. The company states that this presentation is posted on its website and is included as Exhibit 99.1.
The company clarifies that the information in this presentation is being furnished under a disclosure item and is not considered "filed" under securities laws, unless a future document specifically incorporates it by reference. This distinction affects how the information is treated for legal and liability purposes.
Moleculin Biotech updated progress on its pivotal Phase 2B/3 MIRACLE trial of Annamycin plus cytarabine in second-line relapsed/refractory AML. As of February 10, 2026, 35 subjects have been treated, with another 11 in screening or identified, targeting 45 subjects for the first data unblinding.
In the first 30 treated subjects with blinded efficacy data, the company reports a preliminary composite complete remission (CRc) rate of 40%, made up of 30% complete remission (CR) and 10% CR with partial hematologic recovery (CRh). Moleculin highlights that roughly 35% of treated subjects had failed prior venetoclax regimens and that current blinded CR rates are described as 67% higher than historical cytarabine-alone HiDAC trials at about 17–18% CR.
The company continues to report an absence of cardiotoxicity for Annamycin based on safety data from 90 prior trial subjects and expects to reach 45 treated MIRACLE subjects in the first quarter of 2026, with unblinding of the first 45 subjects’ efficacy data anticipated in late second quarter 2026, followed by additional unblindings as Part A of the trial completes.